Research on patients for drug trials to continue in Cuba

Havana, Jul 14 (Prensa Latina) The classification consultations for patients with Alzheimer's disease who will soon be part of the phase III clinical trial of the Cuban neuroprotective drug NeuralCIM (NeuroEPO) will continue in this city on Thursday

One of the advantages of the study is that, thanks to it, no participant will be exempt from treatment, Dr. Nelson Gomez, main researcher at the Hermanos Ameijeiras Surgical Clinical Hospital, one of the care centers where the research is being carried out, said.

The expert noted that the patients will be divided into three groups: one will receive NeuralCIM, another will benefit from Donepezil, a drug approved by the United States Food and Drug Administration since 1996 to treat the disease, and a third will be given the combination from both.

Moreover, for the first time a molecular marker will be introduced for the diagnosis of the disease, since the presence of amyloid beta protein will be determined in people’s cerebrospinal fluid, whose accumulation in the brain is identified as a precursor to Alzheimer’s, he noted.

In addition, he added, a number of individuals will undergo a positron emission tomography study to evaluate brain metabolism, and another will undergo the so-called Spect, which is simple photon emission tomography.

In my opinion, he emphasized, this clinical trial meets all the internationally established rigorous criteria for including patients with Alzheimer’s disease.

NeuralCIM, which already has a conditioned registration granted by the national regulatory authority, also has the potential to be used in the treatment of Parkinson’s, Ataxia and Acute Cerebral Ischemia.

The drug, created by the Center of Molecular Immunology, is nasally administered and seeks to restore the imbalance caused by neurodegenerative conditions in the brain and stabilize its physiological functioning.